Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lean body mass-based oxaliplatin dose normalization in adjuvant stage III colon cancer
2016-002576-27Phase 2Active
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Mar 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in colon cancer (2 arms), sponsored by Institut du Cancer de Montpellier. Started Mar 2017; status: active.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2016-002576-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002576-27.